Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claude Lardinois

Endocrinology, Diabetes & Metabolism Reno, NV Medical Doctor

NPI 1689686677 CMS profile 76725

1700 Aquila Ave, Reno, NV 89509

Open in the dashboard

General payments

$65,008

220 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claude Lardinois of Reno, NV is reported in the CMS Open Payments database as having received $65,008 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,452 16
2024 General $1,621 17
2023 General $1,410 18
2022 General $3,081 18
2021 General $4,083 17
2020 General $7,242 8
2019 General $46,120 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claude Lardinois
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Claude Lardinois were reported at $1,452. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Claude Lardinois Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $46,120 $494 $123–$2,253 $163
2020 $7,242 $335 $85–$1,841 $114
2021 $4,083 $398 $88–$1,981 $132
2022 $3,081 $364 $88–$1,568 $149
2023 $1,410 $420 $113–$1,614 $160
2024 $1,621 $440 $121–$1,646 $164
2025 $1,452 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $35,086 77 payments
  2. Sanofi-Aventis U.S. LLC $12,646 23 payments
  3. Janssen Pharmaceuticals, Inc $8,961 19 payments
  4. Corcept Therapeutics $1,233 14 payments
  5. Xeris Pharmaceuticals, Inc. $1,077 4 payments
  6. Amgen Inc. $672 9 payments
  7. AstraZeneca Pharmaceuticals LP $613 11 payments
  8. Novo Nordisk Inc $610 12 payments
  9. AbbVie, Inc. $413 4 payments
  10. Amarin Pharma Inc. $369 5 payments
  11. Other $3,327 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,177 23 payments
  2. Food and Beverage $10,928 161 payments
  3. Consulting Fee $6,800 3 payments
  4. Travel and Lodging $5,397 28 payments
  5. Honoraria $604 1 payment
  6. Education $103 4 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $30,716 61 payments
  2. INVOKANA $9,110 21 payments
  3. Korlym $1,233 14 payments
  4. JARDIANCE $892 5 payments
  5. TZIELD $737 8 payments
  6. GVOKE PFS $604 1 payment
  7. RECORLEV $473 3 payments
  8. EVENITY $420 6 payments
  9. Vascepa $369 5 payments
  10. TEPEZZA $331 3 payments
  11. Other $4,303 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record